The Medicines Company - Product Pipeline Review - 2016

The Medicines Company - Product Pipeline Review - 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development by The Medicines Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ The Medicines Company - Product Pipeline Review - 2016


Scope

- The report provides a snapshot of the pipeline therapeutic landscape of The Medicines Company
- The report provides overview of The Medicines Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses The Medicines Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features The Medicines Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate The Medicines Company’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for The Medicines Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding The Medicines Company’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Cervical Cancer Global Clinical Trials Review, H1, 2016

Cervical Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Cervical Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Cervical Cancer Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

GlaxoSmithKline Plc Merck & Co., Inc. AstraZeneca Plc F. Hoffmann-La Roche Ltd. Bristol-Myers Squibb Company Pfizer Inc. Sanofi Novartis AG Advaxis, Inc. Eli Lilly and Company




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Peritoneal Cancer Global Clinical Trials Review, H1, 2016

Peritoneal Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Peritoneal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Peritoneal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Peritoneal Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

F. Hoffmann-La Roche Ltd. AstraZeneca Plc Sanofi Eli Lilly and Company GlaxoSmithKline Plc AbbVie Inc. Novartis AG Merck & Co., Inc. Bayer AG Amgen Inc.


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Endometrial Cancer Global Clinical Trials Review, H1, 2016

Endometrial Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Endometrial Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Endometrial Cancer Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

AstraZeneca Plc Novartis AG F. Hoffmann-La Roche Ltd. Merck & Co., Inc. GlaxoSmithKline Plc Sanofi Bristol-Myers Squibb Company Pharma Mar, S.A. Pfizer Inc. Eisai Co., Ltd.



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hyperparathyroidism Global Clinical Trials Review, H1, 2016

Hyperparathyroidism Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Hyperparathyroidism clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperparathyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Hyperparathyroidism Global Clinical Trials Review, H1, 2016
Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

Amgen Inc. AbbVie Inc. Sanofi OPKO Health, Inc. Abbott Laboratories Kirin Holdings Company, Limited Kirin Brewery Co., Ltd. Astellas Pharma Inc. Ono Pharmaceutical Co., Ltd. Deltanoid Pharmaceuticals Inc.



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Anal Cancer Global Clinical Trials Review, H1, 2016

Anal Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Anal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Anal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Anal Cancer Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

The EMMES Corporation Merck & Co., Inc. F. Hoffmann-La Roche Ltd. Advaxis, Inc. Oryx GmbH & Co. KG Accuray Incorporated AbbVie Inc. Axon Laboratories Private Limited Amgen Inc. AKELA Pharma Inc.




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Thymus Cancer Global Clinical Trials Review, H1, 2016

Thymus Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Thymus Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Thymus Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Thymus Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

Novartis AG Tiziana Life Sciences Plc Merck & Co., Inc. Ipsen S.A. F. Hoffmann-La Roche Ltd. Eli Lilly and Company AstraZeneca Plc Advanced Accelerator Applications S.A. AbbVie Inc. Celgene Corporation




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Vaginal Cancer Global Clinical Trials Review, H1, 2016

Vaginal Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Vaginal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Vaginal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Vaginal Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Merck & Co., Inc. ISA Pharmaceuticals B.V. GlaxoSmithKline Plc F. Hoffmann-La Roche Ltd. Bristol-Myers Squibb Company Oryx GmbH & Co. KG Kirin Holdings Company, Limited Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Ariad Pharmaceuticals, Inc. Advaxis, Inc.




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Laryngeal Cancer Global Clinical Trials Review, H1, 2016

Laryngeal Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Laryngeal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Laryngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Laryngeal Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

AstraZeneca Plc Amgen Inc. F. Hoffmann-La Roche Ltd. Merck & Co., Inc. Bristol-Myers Squibb Company C. H. Boehringer Sohn AG & Co. KG Astellas Pharma Inc. GlaxoSmithKline Plc E. Merck KG Novartis AG



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Thyroid Cancer Global Clinical Trials Review, H1, 2016

Thyroid Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Thyroid Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Thyroid Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Thyroid Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

AstraZeneca Plc Eisai Co., Ltd. Pfizer Inc. Novartis AG GlaxoSmithKline Plc Bayer AG Sanofi F. Hoffmann-La Roche Ltd. Exelixis, Inc. Quintiles Transnational Holdings Inc.


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Burkitt Lymphoma Global Clinical Trials Review, H1, 2016

Burkitt Lymphoma Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Burkitt Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Burkitt Lymphoma Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

Takeda Pharmaceutical Company Limited F. Hoffmann-La Roche Ltd. Sanofi Novartis AG Celgene Corporation Pfizer Inc. AbbVie Inc. Seattle Genetics, Inc. Johnson & Johnson Amgen Inc.



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hyperthyroidism Global Clinical Trials Review, H1, 2016

Hyperthyroidism Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Hyperthyroidism clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperthyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Hyperthyroidism Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

PTP Science Park Novartis AG M. S. J. Industries (Ceylon)(Private) Ltd. Laboratoires Pierre Fabre SA E. Merck KG Cultech Limited biosyn Arzneimittel GmbH AbbVie Inc.




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Cervical Cancer Global Clinical Trials Review, H1, 2016

Cervical Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This reportprovides an overview of Cervical Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Cervical Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Cervical Cancer Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

GlaxoSmithKline Plc Merck & Co., Inc. AstraZeneca Plc F. Hoffmann-La Roche Ltd. Bristol-Myers Squibb Company Pfizer Inc. Sanofi Novartis AG Advaxis, Inc. Eli Lilly and Company


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Gastric Cancer Global Clinical Trials Review, H1, 2016

Gastric Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report  provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Gastric Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

F. Hoffmann-La Roche Ltd. Sanofi AstraZeneca Plc Otsuka Holdings Co., Ltd. Pfizer Inc. Novartis AG Eli Lilly and Company Bristol-Myers Squibb Company GlaxoSmithKline Plc Amgen Inc.



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Gallbladder Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This reportprovides an overview of Gallbladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gallbladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Gallbladder Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

AstraZeneca Plc Sanofi F. Hoffmann-La Roche Ltd. Eli Lilly and Company Bayer AG Merck & Co., Inc. C. H. Boehringer Sohn AG & Co. KG Axcan Pharma Inc. Array BioPharma Inc. Amgen Inc.



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Esophageal Cancer Global Clinical Trials Review, H1, 2016

Esophageal Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Esophageal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Esophageal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Esophageal Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

Sanofi F. Hoffmann-La Roche Ltd. Bristol-Myers Squibb Company Pfizer Inc. Novartis AG AstraZeneca Plc Merck & Co., Inc. Amgen Inc. Eli Lilly and Company GlaxoSmithKline Plc



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Fallopian Tube Cancer Global Clinical Trials Review, H1, 2016

Fallopian Tube Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Fallopian Tube Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Fallopian Tube Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Fallopian Tube Cancer Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

F. Hoffmann-La Roche Ltd. AstraZeneca Plc AbbVie Inc. Sanofi Merck & Co., Inc. GlaxoSmithKline Plc Novartis AG Eli Lilly and Company Bayer AG Amgen Inc.


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Testicular Cancer Global Clinical Trials Review, H1, 2016

Testicular Cancer Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report  provides an overview of Testicular Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Testicular Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Testicular Cancer Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Merck & Co., Inc. Bristol-Myers Squibb Company Bayer AG ZIOPHARM Oncology, Inc. Sanofi Pfizer Inc. AbbVie Inc. A. Menarini Industrie Farmaceutiche Riunite Srl Amgen Inc. Actinium Pharmaceuticals, Inc.




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Ewing Sarcoma Global Clinical Trials Review, H1, 2016

Ewing Sarcoma Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Ewing Sarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Ewing Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Ewing Sarcoma Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Eli Lilly and Company F. Hoffmann-La Roche Ltd. Amgen Inc. Children's Healthcare of Atlanta Inc. Merck & Co., Inc. Pharma Mar, S.A. Novartis AG Gradalis Inc. GlaxoSmithKline Plc BioMarin Pharmaceutical Inc.




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Vascular Dementias Global Clinical Trials Review, H1, 2016

Vascular Dementias Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides an overview of Vascular Dementias clinical trials scenario. This report provides top line data relating to the clinical trials on Vascular Dementias. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Vascular Dementias Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Johnson & Johnson Pfizer Inc. Novartis AG Shionogi & Co., Ltd. Eisai Co., Ltd. Bayer AG AstraZeneca Plc acromion GmbH Abbott Laboratories A2 Healthcare Taiwan Corporation



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Humabs BioMed SA - Product Pipeline Review - 2016

Humabs BioMed SA - Product Pipeline Review - 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development by Humabs BioMed SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Humabs BioMed SA - Product Pipeline Review - 2016


Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Humabs BioMed SA
- The report provides overview of Humabs BioMed SA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Humabs BioMed SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Humabs BioMed SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Humabs BioMed SA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Humabs BioMed SA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Humabs BioMed SA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Pneumocystis Infection - Pipeline Review, H1 2016

Pneumocystis Infection - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the Bradykinin B1 Receptor (B1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Pneumocystis Infection - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape for Bradykinin B1 Receptor (B1R)
- The report reviews Bradykinin B1 Receptor (B1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bradykinin B1 Receptor (B1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bradykinin B1 Receptor (B1R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bradykinin B1 Receptor (B1R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bradykinin B1 Receptor (B1R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Companies Mentioned

Axxam SpA Boehringer Ingelheim GmbH Dompe Farmaceutici S.p.A. Grunenthal GmbH


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2016

Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the Bradykinin B1 Receptor (B1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape for Bradykinin B1 Receptor (B1R)
- The report reviews Bradykinin B1 Receptor (B1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bradykinin B1 Receptor (B1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bradykinin B1 Receptor (B1R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bradykinin B1 Receptor (B1R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bradykinin B1 Receptor (B1R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Companies Mentioned

Axxam SpA Boehringer Ingelheim GmbH Dompe Farmaceutici S.p.A. Grunenthal GmbH


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Obesity - Pipeline Review, H1 2016

Obesity - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Obesity - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Obesity
- The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects
- The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Obesity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Abeome Corporation Advinus Therapeutics Ltd. Aegis Therapeutics, LLC Akron Molecules AG Alize Pharma SAS Amabiotics SAS Ambrx, Inc. Amgen Inc. Arena Pharmaceuticals, Inc. AstraZeneca Plc Asubio Pharma Co., Ltd. AtheroNova Inc. Athersys, Inc. Avaxia Biologics, Inc. BioLingus AG Biophytis SAS BioRestorative Therapies, Inc. BioTime, Inc. Boehringer Ingelheim GmbH Braasch Biotech LLC Bristol-Myers Squibb Company Camurus AB Carmot Therapeutics, Inc. Chronos Therapeutics Limited CohBar, Inc. CoMentis, Inc. Corium International, Inc. Daiichi Sankyo Company, Limited Diabetica Limited DiscoveryBiomed, Inc. Eisai Co., Ltd. Eli Lilly and Company Esperion Therapeutics, Inc. Eternygen GmbH Euroscreen S.A. F. Hoffmann-La Roche Ltd. FibroGen, Inc. Galenea Corp. GlaxoSmithKline Plc GTx, Inc. HanAll Biopharma Co., Ltd. Handok Inc. Hanmi Pharmaceuticals, Co. Ltd. Helsinn Healthcare S.A. Hyundai Pharmaceutical Co., Ltd. Immungenetics AG Intarcia Therapeutics, Inc. Ionis Pharmaceuticals, Inc. Jenrin Discovery, Inc. Johnson & Johnson Kissei Pharmaceutical Co., Ltd. Kowa Company, Ltd. Lead Discovery Center GmbH LEO Pharma A/S LG Life Science LTD. Magnus Life Science MAKScientific, LLC MedImmune, LLC Merck & Co., Inc. Mitochon Pharmaceuticals, Inc. Mitsubishi Tanabe Pharma Corporation Molecular Design International, Inc. NGM Biopharmaceuticals, Inc. Nimbus Therapeutics, LLC nLife Therapeutics, S.L. Nordic Bioscience A/S Novo Nordisk A/S ObeTherapy Biotechnology Omeros Corporation OPKO Health, Inc. Orbis Biosciences, Inc. Orexigen Therapeutics, Inc. Pfizer Inc. PharmaIN Corporation Progenra, Inc. Prometheon Pharma, LLC Reviva Pharmaceuticals Inc. Rhythm Pharmaceuticals, Inc. Saniona AB Sanofi Shanghai Pharmaceutical Co., Ltd. Shionogi & Co., Ltd. Sinil Pharmaceutical Co., Ltd Sirona Biochem Corp Sorrento Therapeutics, Inc. Sumitomo Dainippon Pharma Co., Ltd. Suven Life Sciences Ltd. Takeda Pharmaceutical Company Limited Toray Industries, Inc. Transition Therapeutics Inc. Umecrine AB Vicore Pharma AB Viking Therapeutics, Inc. WhanIn Pharmaceutical Co., Ltd. Xenetic Biosciences (UK) Limited XL-protein GmbH Zafgen Inc. Zealand Pharma A/S


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Haemophilus influenzae Type B Infections - Pipeline Review, H1 2016

Haemophilus influenzae Type B Infections - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Haemophilus influenzae Type B Infections - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections
- The report reviews pipeline therapeutics for Haemophilus influenzae Type B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Haemophilus influenzae Type B Infections therapeutics and enlists all their major and minor projects
- The report assesses Haemophilus influenzae Type B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Beijing Minhai Biotechnology Co., Ltd Biological E. Limited Daiichi Sankyo Company, Limited Indian Immunologicals Limited LG Life Science LTD. Panacea Biotec Limited Sanofi Pasteur SA Sinovac Biotech Ltd. Zydus Cadila Healthcare Limited

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG
- The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bayer AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bayer AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bayer AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bayer AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
- The report reviews pipeline therapeutics for Genital Warts (Condylomata Acuminata) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Genital Warts (Condylomata Acuminata) therapeutics and enlists all their major and minor projects
- The report assesses Genital Warts (Condylomata Acuminata) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Genital Warts (Condylomata Acuminata)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Agilvax, Inc. Aviragen Therapeutics, Inc. Biogenomics Limited BioMAS Ltd. Foamix Pharmaceuticals Ltd. G&E Herbal Biotechnology Co., Ltd. Helix BioPharma Corp. Laboratories Ojer Pharma S.L. LEO Pharma A/S Novan, Inc. Novartis AG Tamir Biotechnology, Inc. Zydus Cadila Healthcare Limited



Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Pompe Disease - Pipeline Review, H1 2016

Pompe Disease - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Pompe Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pompe Disease and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Pompe Disease - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Pompe Disease
- The report reviews pipeline therapeutics for Pompe Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pompe Disease therapeutics and enlists all their major and minor projects
- The report assesses Pompe Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pompe Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pompe Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pompe Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Alexion Pharmaceuticals, Inc. Amicus Therapeutics, Inc. Audentes Therapeutics, Inc. BioMarin Pharmaceutical Inc. EpiVax, Inc. Etubics Corporation Genzyme Corporation Greenovation Biotech GmbH Oxyrane Belgium NV Pharming Group N.V. RespireRx Pharmaceuticals Inc. Sarepta Therapeutics, Inc.


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###